Constipation - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 102 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Constipation - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Constipation - Pipeline Review, H2 2014', provides an overview of the Constipation's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Constipation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Constipation and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Constipation
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Constipation and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Constipation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Constipation pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Constipation
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Constipation pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Constipation Overview 8
Therapeutics Development 9
Pipeline Products for Constipation - Overview 9
Pipeline Products for Constipation - Comparative Analysis 10
Constipation - Therapeutics under Development by Companies 11
Constipation - Therapeutics under Investigation by Universities/Institutes 14
Constipation - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Constipation - Products under Development by Companies 19
Constipation - Products under Investigation by Universities/Institutes 20
Constipation - Companies Involved in Therapeutics Development 21
AstraZeneca PLC 21
Daiichi Sankyo Company, Limited 22
Sumitomo Dainippon Pharma Co., Ltd. 23
Astellas Pharma Inc. 24
Kissei Pharmaceutical Co., Ltd. 25
Teva Pharmaceutical Industries Limited 26
Shire Plc 27
AlbireoPharma 28
Sanwa Kagaku Kenkyusho Co., Ltd. 29
Sucampo Pharmaceuticals, Inc. 30
Ironwood Pharmaceuticals, Inc. 31
Synergy Pharmaceuticals, Inc. 32
Braintree Laboratories, Inc. 33
Beech Tree Labs, Inc. 34
Rhythm Pharmaceuticals 35
SK Biopharmaceuticals Co., Ltd. 36
Dong-A Socio Group 37
Constipation - Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Target 39
Assessment by Mechanism of Action 41
nnnnAssessment by Route of Administration 42
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 47
prucalopride succinate - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
linaclotide - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
lubiprostone - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
plecanatide - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
elobixibat - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
tenapanor - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
LP-101 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
relamorelin - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
YKP-GI - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
BLI-801 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
DSP-6952 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
KWA-0711 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
STD-07 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
DA-6886 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
DS-3801 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
MDT-006 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Small Molecule for Chronic Constipation - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
ASP-7663 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
5-BOIP - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Transilon - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
SK-1202 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Constipation - Recent Pipeline Updates 76
Constipation - Dormant Projects 93
Constipation - Product Development Milestones 94
Featured News & Press Releases 94
Jul 14, 2014: Synergy Pharmaceuticals Reaches Halfway Mark for the First Pivotal Phase 3 Trial of Plecanatide in Patients with Chronic Idiopathic Constipation 94
May 06, 2014: Rhythm Presents Positive GI Motility Results for Relamorelin (RM-131) in Phase 2 Chronic Constipation Study 94
May 01, 2014: Sucampo Announces Clinical Data on Lubiprostone to be Presented at Two Upcoming Scientific Conferences 95
Apr 28, 2014: Synergy Pharmaceuticals Initiates Second Phase 3 Clinical Trial of Plecanatide in Patients with Chronic Idiopathic Constipation 96
Apr 25, 2014: Sucampo Pharma To Present Preclinical Data For Lubiprostone at Experimental Biology Conference 2014 96
Mar 14, 2014: Sucampo and Takeda Announce Update on Liquid Formulation Program for AMITIZA (lubiprostone) 97
Feb 06, 2014: All Physicians in Switzerland Are Now Able to Prescribe Sucampo's AMITIZA for Chronic Idiopathic Constipation 97
Dec 17, 2013: Sucampo and Takeda Initiate Global Pivotal Phase 3 Program of Lubiprostone in Pediatric Functional Constipation 98
Nov 13, 2013: Synergy Pharmaceuticals Initiates First Phase 3 Clinical Trial of Plecanatide in Patients with Chronic Idiopathic Constipation 99
Oct 23, 2013: Sucampo and Takeda Initiate Pivotal Trial of Lubiprostone Liquid Formulation in Adults With Chronic Idiopathic Constipation 100
Appendix 101
Methodology 101
Coverage 101
Secondary Research 101
Primary Research 101
Expert Panel Validation 101
Contact Us 102
Disclaimer 102

List of Tables
Number of Products under Development for Constipation, H2 2014 9
Number of Products under Development for Constipation - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Number of Products under Development by Companies, H2 2014 (Contd..1) 13
Number of Products under Investigation by Universities/Institutes, H2 2014 14
Comparative Analysis by Late Stage Development, H2 2014 15
Comparative Analysis by Clinical Stage Development, H2 2014 16
Comparative Analysis by Early Stage Development, H2 2014 17
Comparative Analysis by Unknown Stage Development, H2 2014 18
Products under Development by Companies, H2 2014 19
Products under Investigation by Universities/Institutes, H2 2014 20
Constipation - Pipeline by AstraZeneca PLC, H2 2014 21
Constipation - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 22
Constipation - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2014 23
Constipation - Pipeline by Astellas Pharma Inc., H2 2014 24
Constipation - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2014 25
Constipation - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 26
Constipation - Pipeline by Shire Plc, H2 2014 27
Constipation - Pipeline by AlbireoPharma, H2 2014 28
Constipation - Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H2 2014 29
Constipation - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2014 30
Constipation - Pipeline by Ironwood Pharmaceuticals, Inc., H2 2014 31
Constipation - Pipeline by Synergy Pharmaceuticals, Inc., H2 2014 32
Constipation - Pipeline by Braintree Laboratories, Inc., H2 2014 33
Constipation - Pipeline by Beech Tree Labs, Inc., H2 2014 34
Constipation - Pipeline by Rhythm Pharmaceuticals, H2 2014 35
Constipation - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2014 36
Constipation - Pipeline by Dong-A Socio Group, H2 2014 37
Assessment by Monotherapy Products, H2 2014 38
Number of Products by Stage and Target, H2 2014 40
Number of Products by Stage and Mechanism of Action, H2 2014 42
Number of Products by Stage and Route of Administration, H2 2014 44
Number of Products by Stage and Molecule Type, H2 2014 46
Constipation Therapeutics - Recent Pipeline Updates, H2 2014 76
Constipation - Dormant Projects, H2 2014 93